Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
The company expects meaningful revenue contribution from this long-term agreement
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
CRL shall invest another Rs. 200 crore for creation of additional beds
She has held senior positions at Coca-Cola in China and PepsiCo in India
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Subscribe To Our Newsletter & Stay Updated
